<DOC>
	<DOCNO>NCT03089229</DOCNO>
	<brief_summary>Atopic dermatitis ( AD ) chronic inflammatory skin disease characterize disturbance epidermal-barrier function result intensely pruritic subacute chronic eczematous plaque . The current therapy AD reactive , flare treat symptomatic management topical corticosteroid calcineurin inhibitor . Given medication long-term side-effects , give chronically relapse immunopathogenic nature AD , imperative need safer anti-inflammatory medication . Haus Bioceuticals ( Haus ) develop novel topical treatment eczema/atopic dermatitis ( AD ) denote HAT01H , demonstrate HAT01H safe profoundly effective treatment AD , control sign symptom 85 % patient AD . This study aim test efficacy safety topical HAT01H patient moderate severe atopic dermatitis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety HAT01H Atopic Dermatitis</brief_title>
	<detailed_description>This study 13 week ( 91 day ) randomize , double-blind , home use study among 30 male female subject moderate severe active atopic dermatitis ( AD ) . The study include subject age 12 - 65 year old inclusive . Group assignments balance age disease severity AD . The study consist 1 week washout period 12 week treatment phase . During treatment phase , subject provide one two test product use twice daily lesion non-lesional area instruct . No additional cream , lotion soap provide test product allow throughout duration study . Measurements , expert visual assessment self-assessments take described . Safety tolerability evaluate incidence AE 's ( define per CTCAE ) , exacerbation , application site reactions/infections , lab evals . There also consumption/compliance check dermatological evaluation visit .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Moderate severe atopic dermatitis determine PGA â‰¥ 3 SCORAD &gt; 25 Males female , age 12 65 year old inclusive Is currently participate participate another interventional clinical study facility past 3 month . Currently diagnose treat cancer past 5 year . Requires topical systemic medication could affect course atopic dermatitis study period ( except inhale steroid and/or stable antihistamine asthma allergy ) . Has know hypersensitivity corticosteroid cream . Has active infection use antibiotic past 7 day . Has physical attribute skin condition might interfere clear visual assessment ( i.e . cut , sunburn , birth mark , tattoo , extensive scarring , excessive hair growth acne ) Has immunologic infectious disease ( e.g . hepatitis , tuberculosis , HIV AIDS , lupus , rheumatoid arthritis ) could place subject risk interfere accuracy study result . Has use immunosuppressant drug immunotherapy within past 30 day 5 halflives . Is employee sponsor company clinical test site . Is dependent oral medication skin disease/condition could , opinion Investigator tolerate restriction discontinue medicine require study . Is currently pregnant lactate plan become pregnant next 6 month ( use double contraception prevention ) . Any condition factor Investigator duly assign representative believe may affect ability subject complete study interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Topical Cream</keyword>
	<keyword>Novel</keyword>
</DOC>